Surgical Procedure Efficiency Evaluation stuDy
Surgical Procedure Efficiency Evaluation stuDy (SPEED): Combination Phaco-Vitrectomy Surgeries With UNITY VCS vs. Constellation in a Real-World Operating Room Setting
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Alcon Call Center
- Phone Number: 1-888-451-3937
- Email: alcon.medinfo@alcon.com
Study Locations
-
-
-
Manchester, United Kingdom, M13 9WL
- Recruiting
- Manchester Royal Eye Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Key Inclusion Criteria:
- Able to understand and sign an informed consent form (ICF) that has been approved by an ethics committee.
- Planned combined phacovitrectomy procedure at one of the selected surgical sites.
- Planned combined phacovitrectomy procedure with 25-gauge (G) vitrectomy tools.
Key Exclusion Criteria:
- Unplanned/emergency phacovitrectomy.
- Pregnant.
- Past history of phacovitrectomy. cataract, vitrectomy in the planned operative eye.
- Other protocol-defined exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
UNITY VCS
Subjects will undergo routine scheduled combined anterior-posterior segments surgery (phacovitrectomy)
|
UNITY® VCS is a CE-marked, FDA-approved ophthalmic microsurgical system that is indicated for both anterior segment (i.e., phacoemulsification and removal of cataracts) and posterior segment (i.e., vitreoretinal) ophthalmic surgery.
The focus of this study will be on combined anterior-posterior segments surgery (phacovitrectomy).
Other Names:
|
|
CONSTELLATION
Subjects will undergo routine scheduled combined anterior-posterior segments surgery (phacovitrectomy)
|
CONSTELLATION is a CE-marked, FDA-approved ophthalmic microsurgical system that is indicated for both anterior segment (i.e., phacoemulsification and removal of cataracts) and posterior segment (i.e., vitreoretinal) ophthalmic surgery.
The focus of this study will be on combined anterior-posterior segments surgery (phacovitrectomy).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of surgeons replying "efficient" or "very efficient" to the question, "How would you rate overall OR (operating room) efficiency of the console for the combined phaco-vitrectomy surgery (including set-up/tear-down)?
Time Frame: Up to Day 1 post completion of the surgery
|
Responses will be collected on a 5-point scale where 1=Very Inefficient, 2=Inefficient, 3=Neutral, 4=Efficient, and 5=Very Efficient.
|
Up to Day 1 post completion of the surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Manager, Health Economics/Outcomes Research, Alcon Research, LLC
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CTV678-H003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitreous Hemorrhage
-
NCT04153253CompletedDiabetic Vitreous Hemorrhage
-
NCT05318742RecruitingDiabetic Vitreous Hemorrhage
-
NCT00300014UnknownPost Vitrectomy State | Recurrent Diabetic Vitreous Hemorrhage
-
NCT04676256CompletedRetinal Detachment | Retinal Break | Spontaneous Vitreous Hemorrhage
-
NCT05739539CompletedTractional Retinal Detachment | Diabetic Vitreous Hemorrhage
-
NCT01151722Unknown
-
NCT05588037RecruitingVitreous Hemorrhage | Cataract | Rhegmatogenous Retinal Detachment | Epiretinal Membrane | Macular Disease | Vitreomacular Traction | Vitreous Cloudy
-
NCT04404296RecruitingVitreous Hemorrhage | Retinal Detachment | Epiretinal Membrane | Vitrectomy | Macular Holes | Dislocated Intraocular Lens Into Vitreous | Retained Lens Fragments
-
NCT01091896UnknownVitreous Hemorrhage Secondary to PDR
-
NCT04859556CompletedVitreous Hemorrhage | Retinal Detachment | Epiretinal Membrane | Macula Hole
Clinical Trials on UNITY VCS
-
NCT07054281WithdrawnProliferative Diabetic Retinopathy | Vitreous Hemorrhage | Rhegmatogenous Retinal Detachment | Epiretinal Membrane | Vitreomacular Traction | Macular Hole | Visually Significant Vitreous Floater | Retained Lens Material in the Posterior Segment
-
NCT06165744CompletedVitreoretinal Disease With or Without Cataracts
-
NCT07222150Recruiting
-
NCT02786615CompletedSubstance-Related Disorders | HIV
-
NCT02145455CompletedArthritis of the Knee
-
NCT04946019CompletedNon-small Cell Lung Cancer